Eurobio Scientific SA
PAR:ALERS
Eurobio Scientific SA
Long-Term Debt
Eurobio Scientific SA
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Eurobio Scientific SA
PAR:ALERS
|
Long-Term Debt
€78.7m
|
CAGR 3-Years
84%
|
CAGR 5-Years
43%
|
CAGR 10-Years
21%
|
|
|
Valneva SE
PAR:VLA
|
Long-Term Debt
€193m
|
CAGR 3-Years
23%
|
CAGR 5-Years
19%
|
CAGR 10-Years
11%
|
|
|
Nanobiotix SA
PAR:NANO
|
Long-Term Debt
€42.7m
|
CAGR 3-Years
1%
|
CAGR 5-Years
2%
|
CAGR 10-Years
44%
|
|
|
Innate Pharma SA
PAR:IPH
|
Long-Term Debt
€68.5m
|
CAGR 3-Years
9%
|
CAGR 5-Years
49%
|
CAGR 10-Years
33%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Long-Term Debt
€59.8m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
48%
|
|
|
Inventiva SA
PAR:IVA
|
Long-Term Debt
€46.8m
|
CAGR 3-Years
67%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Eurobio Scientific SA
Glance View
Eurobio-Scientific SA engages in designing, development and commercialization of tests diagnosis in the fields of transplantation, infectious diseases, autoimmunity and oncology, as well as products for research in the field of life sciences. The company is headquartered in Les Ulis, Ile-De-France. The company went IPO on 2005-11-18. The company is engaged in activities ranging from discovery to the commercialization of specialty diagnostic products. The firm owns a portfolio of diagnostic products in three specialty areas: infectious diseases; Alzheimer's disease, and cancer. The company consists of Tetanos Quick Stick (TQS), which is an unitary test enabling to determine the tetanus vaccination status. The company has a portfolio of in-house and co-developed products, including AclarusDx (a blood-based test for the detection of biomarkers specific for Alzheimer's disease). The portfolio includes BJI Inoplex for prosthetic infections and EHT Dx14 for breast cancer (both in validation phase). The co-developed products include research programs for the identification of predictive biomarkers of response for anti-HER2 and anti-angiogenic therapies, among others. The company operates through Genbio and Eurobio Capforce Plus.
See Also
What is Eurobio Scientific SA's Long-Term Debt?
Long-Term Debt
78.7m
EUR
Based on the financial report for Jun 30, 2024, Eurobio Scientific SA's Long-Term Debt amounts to 78.7m EUR.
What is Eurobio Scientific SA's Long-Term Debt growth rate?
Long-Term Debt CAGR 10Y
21%
Over the last year, the Long-Term Debt growth was -15%. The average annual Long-Term Debt growth rates for Eurobio Scientific SA have been 84% over the past three years , 43% over the past five years , and 21% over the past ten years .
You don't have any saved screeners yet